Literature DB >> 12642018

Angiotensin II and the glomerulus: focus on diabetic kidney disease.

James W Scholey1.   

Abstract

The renin-angiotensin system plays a key role in the progression of kidney disease, in addition to its well-described role in the maintenance of extracellular fluid volume and blood pressure. Recent studies have shown that blockade of the renin-angiotensin system at the level of the angiotensin II type 1 receptor can have important effects on proteinuria and the rate of progression of kidney disease in patients with type 2 diabetes mellitus. This review first discusses recent experimental studies relating angiotensin II to kidney function in diabetes mellitus and changes in glomerular permselectivity, and then focuses on recent clinical trials with angiotensin II receptor blockers in patients with type 2 diabetes mellitus.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12642018     DOI： 10.1007/s11906-003-0075-0

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN： 1522-6417            Impact factor:   5.369


  63 in total

1.  Angiotensin II stimulates expression of the chemokine RANTES in rat glomerular endothelial cells. Role of the angiotensin type 2 receptor.

Authors:  G Wolf; F N Ziyadeh; F Thaiss; J Tomaszewski; R J Caron; U Wenzel; G Zahner; U Helmchen; R A Stahl
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

2.  Direct stimulation of Jak/STAT pathway by the angiotensin II AT1 receptor.

Authors:  M B Marrero; B Schieffer; W G Paxton; L Heerdt; B C Berk; P Delafontaine; K E Bernstein
Journal:  Nature       Date:  1995-05-18       Impact factor: 49.962

3.  The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.

Authors:  H H Parving; H Lehnert; J Bröchner-Mortensen; R Gomis; S Andersen; P Arner
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

4.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.

Authors: 
Journal:  Lancet       Date:  2000-01-22       Impact factor: 79.321

5.  Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice.

Authors:  F N Ziyadeh; B B Hoffman; D C Han; M C Iglesias-De La Cruz; S W Hong; M Isono; S Chen; T A McGowan; K Sharma
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

6.  Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension.

Authors:  R Zatz; B R Dunn; T W Meyer; S Anderson; H G Rennke; B M Brenner
Journal:  J Clin Invest       Date:  1986-06       Impact factor: 14.808

7.  Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-beta levels.

Authors:  Rajiv Agarwal; Senthuran Siva; Stephen R Dunn; Kumar Sharma
Journal:  Am J Kidney Dis       Date:  2002-03       Impact factor: 8.860

8.  Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect.

Authors:  Giancarlo Viberti; Nigel M Wheeldon
Journal:  Circulation       Date:  2002-08-06       Impact factor: 29.690

9.  Angiotensin II stimulates human fetal mesangial cell proliferation and fibronectin biosynthesis by binding to AT1 receptors.

Authors:  P E Ray; L A Bruggeman; S Horikoshi; G Aguilera; P E Klotman
Journal:  Kidney Int       Date:  1994-01       Impact factor: 10.612

10.  Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis.

Authors:  D E Vaughan; S A Lazos; K Tong
Journal:  J Clin Invest       Date:  1995-03       Impact factor: 14.808
View more
  1 in total

1.  Pharmacokinetics of gentamicin in hemodialysis patients: a comparative study between diabetic and non-diabetic patients.

Authors:  Mohammed A Al-Homrany; Yacoub M Irshaid; Assem K El Sherif; Haider A Omar
Journal:  Int Urol Nephrol       Date:  2008-09-03       Impact factor: 2.370
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.